Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.517
EU - Europa 5.834
AS - Asia 4.707
SA - Sud America 334
AF - Africa 45
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 6
Totale 18.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.297
SG - Singapore 2.157
RU - Federazione Russa 1.669
HK - Hong Kong 1.624
IE - Irlanda 1.330
IT - Italia 1.006
DE - Germania 663
SE - Svezia 496
CN - Cina 455
BR - Brasile 289
CA - Canada 182
ID - Indonesia 144
GB - Regno Unito 125
AT - Austria 105
UA - Ucraina 90
IN - India 84
FI - Finlandia 64
NL - Olanda 63
BE - Belgio 44
JP - Giappone 41
VN - Vietnam 34
FR - Francia 32
MX - Messico 31
IR - Iran 23
TR - Turchia 21
DK - Danimarca 19
ES - Italia 19
RO - Romania 18
AR - Argentina 15
KR - Corea 13
EC - Ecuador 12
PK - Pakistan 12
TH - Thailandia 12
MA - Marocco 11
AU - Australia 10
CZ - Repubblica Ceca 10
KZ - Kazakistan 10
NO - Norvegia 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CH - Svizzera 9
PL - Polonia 9
BD - Bangladesh 8
PT - Portogallo 8
IQ - Iraq 7
LV - Lettonia 7
NZ - Nuova Zelanda 7
EG - Egitto 6
LT - Lituania 6
VE - Venezuela 6
CL - Cile 5
DZ - Algeria 5
GR - Grecia 5
HU - Ungheria 5
JO - Giordania 5
PH - Filippine 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
UZ - Uzbekistan 5
EE - Estonia 4
EU - Europa 4
IL - Israele 4
LB - Libano 4
LK - Sri Lanka 4
MY - Malesia 4
SN - Senegal 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
CO - Colombia 3
MD - Moldavia 3
PA - Panama 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
CY - Cipro 2
JM - Giamaica 2
KW - Kuwait 2
MK - Macedonia 2
NG - Nigeria 2
PY - Paraguay 2
SA - Arabia Saudita 2
SC - Seychelles 2
BY - Bielorussia 1
CR - Costa Rica 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
QA - Qatar 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
YE - Yemen 1
Totale 18.460
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.608
Singapore 1.299
Dublin 1.284
Chandler 806
Princeton 744
Ann Arbor 578
New York 479
Frankfurt am Main 460
Ashburn 429
Santa Clara 327
Lawrence 291
Fairfield 288
Altamura 268
Toronto 155
Andover 147
Moscow 145
Jakarta 142
Milan 137
Wilmington 129
Nuremberg 114
Seattle 113
Cambridge 108
San Diego 104
Woodbridge 101
Houston 85
Los Angeles 84
Shanghai 74
Rome 68
Beijing 62
Boardman 59
Pune 53
Helsinki 52
Vienna 52
San Mateo 50
Washington 44
Brussels 40
London 35
Chicago 31
Naples 29
Dong Ket 28
São Paulo 27
Guangzhou 25
Dearborn 22
Cedar Knolls 18
Dallas 18
Nanjing 18
Tokyo 16
Council Bluffs 15
Turin 14
Belo Horizonte 13
Fremont 13
Brescia 12
Lappeenranta 12
Laurel 12
Kilburn 11
Mexico City 11
Padova 11
Bangkok 9
Bologna 9
Jacksonville 9
Rio de Janeiro 9
Silver Spring 9
Aci Castello 8
Bergamo 8
Brasília 8
Jinan 8
Prescot 8
Tianjin 8
Amsterdam 7
Buenos Aires 7
Changsha 7
Copenhagen 7
Guayaquil 7
Hyderabad 7
Manassas 7
Newark 7
Norwalk 7
Riga 7
Zurich 7
Alexandria 6
Almaty 6
Azzano San Paolo 6
Brooklyn 6
Coventry 6
Dhaka 6
Guadalupe 6
Ivry-sur-Seine 6
Leawood 6
Madrid 6
Montréal 6
Oslo 6
Palermo 6
Ribeirão Preto 6
Sacramento 6
San Francisco 6
San Giuliano Milanese 6
Seoul 6
Tabriz 6
Winnipeg 6
Xi'an 6
Totale 11.666
Salva come PNG Salva come JPEG
Nome #
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 417
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 313
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 279
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 224
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 195
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 183
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 179
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 177
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 158
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 158
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 152
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 151
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 142
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 139
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 137
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 127
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 125
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 122
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 114
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 110
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 110
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 102
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 101
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 95
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 93
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 93
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 89
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 89
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 88
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 86
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 82
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 80
An unusual case of cardiac aspergillosis 78
Cardiac contractility modulation in heart failure with reduced ejection fraction: critical review of evidence and application perspectives [Modulazione della contrattilità cardiaca nello scompenso cardiaco a frazione di eiezione ridotta: revisione critica delle evidenze ed aspetti decisionali pratici] 78
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 76
Trattamento conservativo della valvola mitrale in presenza di endocardite infettiva 76
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 76
Evolocumab and clinical outcomes in patients with cardiovascular disease 76
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 75
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 72
Low dosage of cyclosporine and increased occurrence of chronic rejection in heart-transplanted patients 71
Tailored approach to trans-catheter palliation of critically reduced pulmonary blood supply. Data on long term follow up 71
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 69
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 69
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation 69
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 69
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 68
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 67
Ejection fraction of 20% or less is not a contraindication to cardiac surgery 67
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 66
Trapianto cardiaco in età pediatrica: esperienza in 34 casi 65
Surgical ventricular reverse remodeling in severe ischemic dilated cardiomyopathy: The relevance of the left ventricular equator as a prognostic factor 64
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 64
Aspirin Desensitization in Patients with Coronary Artery Disease 64
A 57-year-old man with rapidly progressive pulmonary hypertension 63
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol 63
Pediatric heart transplantation without chronic maintenance steroids 63
Good survival of patients considered too-well for heart transplantation 62
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 62
Postcardiotomy recovery after repair of congenital defects-comparison of extracorporeal membrane oxygenation with ventricular assist device 61
Importanza dell’ecocardiografia transtoracica e transesofagea nell’assistenza cardiocircolatoria meccanica 61
Ruolo dell’ecocardiografia transesofagea nell’indicazione alla terapia chirurgica Delle endocarditi infettive 61
Prognosis of patients in waiting list for heart transplantation a multiparametric analysis 61
Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe 60
Screening of asymptomatic left ventricular diastolic dysfunction (ALVDD) in a high-risk population enrolled in a primary care setting through ECG and natriuretic peptides. The DAVID-BERG study 60
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 60
Therapeutic options in end-stage heart failure. Journal of Molecular and Cellular 58
The PARAGON-HF trial: Missed opportunity or first personalized therapy? [Lo studio PARAGON-HF: Opportunità mancata o prima terapia personalizzata?] 58
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 57
Hemodynamic arterial changes in heart failure: a proposed new paradigm of "Heart and Vessels Failure" 57
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs 57
QRS fragmentation as a possible electrocardiographic diagnostic marker in patients with acute myocarditis: preliminary histopathological validation 56
Chirurgia riparativa della mitrale in età pediatrica. Esperienza in 56 casi operati 56
Effect of changes in flow on the determination of orifice area in the mitral position by pressure half-time 56
Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial 56
Sex-related differences in patients with coronavirus disease 2019: Results of the Cardio-COVID-Italy multicentre study 56
COVID-19 in Heart Transplant Recipients: A Multicenter Analysis of the Northern Italian Outbreak 55
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 54
Can we improve the accuracy of electrocardiographic algorithms for accessory pathway location in children? 54
Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy 54
Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: Insights from paragon-hf 54
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 53
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial 53
Experience of a pediatric electrophysiology clinic during the COVID-19 pandemic 53
Prevention of left ventricular remodelling after acute myocardial infarction: an update 53
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study 53
Cardiovascular and renal outcomes with empagliflozin in heart failure 53
Heart rate and outcome in patients with acute and chronic heart failure [La frequenza cardiaca e la prognosi nello scompenso cardiaco acuto e cronico] 52
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 52
Continuity of care in patients with cardiac failure after acute event [Percorsi e continuità assistenziale nel paziente con scompenso cardiaco dopo evento acuto] 52
Multivariate analysis of survival in patients in waiting list for heart transplantation 51
Empagliflozin in heart failure with a preserved ejection fraction 51
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 51
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 50
Congestive heart failure in elderly patients 50
The Titan can help titin: From micro to macro myocardial elasticity 50
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence? 50
Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment 50
Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure 50
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial 50
Totale 8.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202048 0 0 0 0 0 0 0 0 0 24 19 5
2020/2021757 35 58 93 36 41 49 73 54 66 68 81 103
2021/20222.953 79 76 77 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/20258.329 466 1.221 441 471 1.283 473 1.104 347 1.518 1.005 0 0
Totale 20.016